Octreotide

• UNSPSC Description:

  Octreotide (SMS 201-995) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly[1][2].

• Target Antigen:

  Apoptosis; Somatostatin Receptor

• Type:

  Peptides

• Related Pathways:

  Apoptosis;GPCR/G Protein;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Octreotide.html

• Purity:

  99.64

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45

• Molecular Weight:

  1019.24

• References & Citations:

  [1]Wang XX, et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet?induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118|[2]Kugita M, et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One. 2017 May 18;12(5):e0177934.|[3]Xiao-Xia Wang,et al. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118.Basic Clin Pharmacol Toxicol. 2022 Jun 10.|Biomacromolecules. 2024 Apr 23.|Cell Mol Bioeng. 2022.|Eur J Nucl Med Mol Imaging. 2024 Jul 18.|Faculty of Biological and Environmental Sciences. University of Helsinki Finland. 2018 Dec.|J Pharm Biomed Anal. 11 December 2021, 114518.|J Pharm Biomed Anal. 2022: 115156.|J Pharm Sci. 2022 Oct 10;S0022-3549(22)00454-3.|Mol Cancer. 2024 Sep 20;23(1):205.|Mol Med Rep. 2024 Jun;29(6):90.|Nat Commun. 2023 Feb 21;14(1):962.|Patent. US20240307504A1.|Research Square Print. 2022 Aug.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  83150-76-9